Anti-IgE-terápia: Újabb lehetoség az allergiás asthma kezelésére

Translated title of the contribution: A new way to treat allergic asthma: Anti-IgE therapy

Research output: Contribution to journalArticle

Abstract

Immunoglobulin E (IgE) plays a central role in the pathogenesis of the inflammation of the bronchial mucosa and airway hyperreactivity, which in turn produces the symptoms of allergic bronchial asthma. Omalizumab, the recently developed anti-IgE monoclonal antibody binds to the C ε3 region of the IgE molecule and thus prevents binding of the IgE to the surface of FC εRI receptor bearing cells (mast cells, basophils and antigen presenting dendritic cells). In the absence of cell-bound IgE, these cells are not activated and thus do not release inflammatory mediators and proinflammatory cytokines upon allergen exposition. Treatment with omalizumab significantly decreases the number of bronchial mucosal eosinophils and FC εRI positive cells, and the FC εRI receptor expression of the latter. Double blind controlled clinical studies have demonstrated that omalizumab treatment reduces the number of exacerbations and emergency room visits, the β 2-agonist requirement and the dose of inhaled steroids, improves exspiratory airflow limitation, asthmatic symptoms and asthma-related quality of life in patients with moderate to severe allergic asthma. Low baseline FEV 1, the use of high dose inhaled corticosteroids and a history of emergency asthma treatment in the past year are significant predictors of a better response to omalizumab. Omalizumab is tolerated well by patients. With the exception of local skin reactions, no significant difference in adverse events between patients taking omalizumab and control groups have been reported. According to the GINA (Global Initiative for Asthma) stepwise therapy protocol of asthma, omalizumab is indicated for severe asthmatics whose symptoms can not be controlled by inhaled corticosteroids and long-acting β 2 agonists.

Original languageHungarian
Pages (from-to)949-954
Number of pages6
JournalLege Artis Medicinae
Volume16
Issue number11
Publication statusPublished - Nov 2006

Fingerprint

Passive Immunization
Immunoglobulin E
Asthma
Adrenal Cortex Hormones
Emergency Treatment
Basophils
Antigen-Presenting Cells
Distance Counseling
Omalizumab
Eosinophils
Mast Cells
Allergens
Dendritic Cells
Hospital Emergency Service
Mucous Membrane
Therapeutics
Steroids
Monoclonal Antibodies
Quality of Life
Cytokines

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Anti-IgE-terápia : Újabb lehetoség az allergiás asthma kezelésére. / Magyar, P.

In: Lege Artis Medicinae, Vol. 16, No. 11, 11.2006, p. 949-954.

Research output: Contribution to journalArticle

@article{aa4fdcd715b14267a67d7092680c90d6,
title = "Anti-IgE-ter{\'a}pia: {\'U}jabb lehetos{\'e}g az allergi{\'a}s asthma kezel{\'e}s{\'e}re",
abstract = "Immunoglobulin E (IgE) plays a central role in the pathogenesis of the inflammation of the bronchial mucosa and airway hyperreactivity, which in turn produces the symptoms of allergic bronchial asthma. Omalizumab, the recently developed anti-IgE monoclonal antibody binds to the C ε3 region of the IgE molecule and thus prevents binding of the IgE to the surface of FC εRI receptor bearing cells (mast cells, basophils and antigen presenting dendritic cells). In the absence of cell-bound IgE, these cells are not activated and thus do not release inflammatory mediators and proinflammatory cytokines upon allergen exposition. Treatment with omalizumab significantly decreases the number of bronchial mucosal eosinophils and FC εRI positive cells, and the FC εRI receptor expression of the latter. Double blind controlled clinical studies have demonstrated that omalizumab treatment reduces the number of exacerbations and emergency room visits, the β 2-agonist requirement and the dose of inhaled steroids, improves exspiratory airflow limitation, asthmatic symptoms and asthma-related quality of life in patients with moderate to severe allergic asthma. Low baseline FEV 1, the use of high dose inhaled corticosteroids and a history of emergency asthma treatment in the past year are significant predictors of a better response to omalizumab. Omalizumab is tolerated well by patients. With the exception of local skin reactions, no significant difference in adverse events between patients taking omalizumab and control groups have been reported. According to the GINA (Global Initiative for Asthma) stepwise therapy protocol of asthma, omalizumab is indicated for severe asthmatics whose symptoms can not be controlled by inhaled corticosteroids and long-acting β 2 agonists.",
keywords = "Anti IgE antibody, Asthma therapy, Omalizumab, Severe bronchial asthma",
author = "P. Magyar",
year = "2006",
month = "11",
language = "Hungarian",
volume = "16",
pages = "949--954",
journal = "Lege Artis Medicinae",
issn = "0866-4811",
publisher = "Literatura Medica Publishing House",
number = "11",

}

TY - JOUR

T1 - Anti-IgE-terápia

T2 - Újabb lehetoség az allergiás asthma kezelésére

AU - Magyar, P.

PY - 2006/11

Y1 - 2006/11

N2 - Immunoglobulin E (IgE) plays a central role in the pathogenesis of the inflammation of the bronchial mucosa and airway hyperreactivity, which in turn produces the symptoms of allergic bronchial asthma. Omalizumab, the recently developed anti-IgE monoclonal antibody binds to the C ε3 region of the IgE molecule and thus prevents binding of the IgE to the surface of FC εRI receptor bearing cells (mast cells, basophils and antigen presenting dendritic cells). In the absence of cell-bound IgE, these cells are not activated and thus do not release inflammatory mediators and proinflammatory cytokines upon allergen exposition. Treatment with omalizumab significantly decreases the number of bronchial mucosal eosinophils and FC εRI positive cells, and the FC εRI receptor expression of the latter. Double blind controlled clinical studies have demonstrated that omalizumab treatment reduces the number of exacerbations and emergency room visits, the β 2-agonist requirement and the dose of inhaled steroids, improves exspiratory airflow limitation, asthmatic symptoms and asthma-related quality of life in patients with moderate to severe allergic asthma. Low baseline FEV 1, the use of high dose inhaled corticosteroids and a history of emergency asthma treatment in the past year are significant predictors of a better response to omalizumab. Omalizumab is tolerated well by patients. With the exception of local skin reactions, no significant difference in adverse events between patients taking omalizumab and control groups have been reported. According to the GINA (Global Initiative for Asthma) stepwise therapy protocol of asthma, omalizumab is indicated for severe asthmatics whose symptoms can not be controlled by inhaled corticosteroids and long-acting β 2 agonists.

AB - Immunoglobulin E (IgE) plays a central role in the pathogenesis of the inflammation of the bronchial mucosa and airway hyperreactivity, which in turn produces the symptoms of allergic bronchial asthma. Omalizumab, the recently developed anti-IgE monoclonal antibody binds to the C ε3 region of the IgE molecule and thus prevents binding of the IgE to the surface of FC εRI receptor bearing cells (mast cells, basophils and antigen presenting dendritic cells). In the absence of cell-bound IgE, these cells are not activated and thus do not release inflammatory mediators and proinflammatory cytokines upon allergen exposition. Treatment with omalizumab significantly decreases the number of bronchial mucosal eosinophils and FC εRI positive cells, and the FC εRI receptor expression of the latter. Double blind controlled clinical studies have demonstrated that omalizumab treatment reduces the number of exacerbations and emergency room visits, the β 2-agonist requirement and the dose of inhaled steroids, improves exspiratory airflow limitation, asthmatic symptoms and asthma-related quality of life in patients with moderate to severe allergic asthma. Low baseline FEV 1, the use of high dose inhaled corticosteroids and a history of emergency asthma treatment in the past year are significant predictors of a better response to omalizumab. Omalizumab is tolerated well by patients. With the exception of local skin reactions, no significant difference in adverse events between patients taking omalizumab and control groups have been reported. According to the GINA (Global Initiative for Asthma) stepwise therapy protocol of asthma, omalizumab is indicated for severe asthmatics whose symptoms can not be controlled by inhaled corticosteroids and long-acting β 2 agonists.

KW - Anti IgE antibody

KW - Asthma therapy

KW - Omalizumab

KW - Severe bronchial asthma

UR - http://www.scopus.com/inward/record.url?scp=33845264170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845264170&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33845264170

VL - 16

SP - 949

EP - 954

JO - Lege Artis Medicinae

JF - Lege Artis Medicinae

SN - 0866-4811

IS - 11

ER -